ArticleJournal of molecular medicine (Berlin, Germany)2026
Gsα deficiency in macrophages promotes tumor progression via the MAPK signaling pathway.
Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
Abstract
Under diverse stimuli in the tumor microenvironment, tumor-associated macrophages (TAMs) are susceptible to polarize toward an immunosuppressive phenotype. Reprogramming TAMs is a promising strategy for cancer immunotherapy. As a downstream molecule of G protein-coupled receptors, the alpha subunit of the stimulatory G protein (Gsα) plays an indispensable role in the transduction of extracellular signals to intracellular signals. However, whether Gsα is responsible for the reprogramming and polarization of TAMs is largely unknown. Here, we demonstrate that Gsα deficiency in TAMs accelerates tumor growth and metastasis in B16 and MC38 tumor cells. Further investigations revealed that Gsα upregulates the expression of CD86, CCR5, Il1b and Nos2 and inhibits CD206 and Il10 expression, which facilitates the recruitment and antitumoral activity of TAMs and contributes to the increased effector activity of CD8
Indexed as
Identifiers
41854744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.